Revolution Medicines (NASDAQ:RVMD) surged 33% on Monday after announcing positive topline findings from its Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma patients.
The study achieved all primary and key secondary endpoints, including both progression-free survival and overall survival. Daraxonrasib delivered a median overall survival of 13.2 months, compared with 6.7 months for standard chemotherapy, corresponding to a hazard ratio of 0.40.
The company said it plans to submit the data to global regulators, including the U.S. Food and Drug Administration, as part of a future New Drug Application under a Commissioner’s National Priority Voucher. Full results are scheduled to be presented at the 2026 American Society of Clinical Oncology Annual Meeting.
Daraxonrasib is designed as a multi-selective inhibitor targeting RAS(ON) proteins, aiming to address cancers driven by oncogenic RAS mutations. Pancreatic cancer is considered one of the most RAS-dependent cancers, with more than 90% of patients carrying tumors linked to RAS mutations.
The RASolute 302 trial included patients with a broad range of RAS variants, as well as individuals without identified RAS mutations. Primary endpoints focused on progression-free and overall survival in patients with RAS G12-mutant tumors, while secondary endpoints evaluated outcomes across the full study population.
Following the first interim analysis, the company confirmed that all progression-free survival and overall survival results are now considered final.